Evidence map›Paper›PMID 34725058›Full record

ArticleBMJ case reports2021

Disseminated blastomycosis in a patient with polycythemia vera on ruxolitinib.

Kristen Zeitler, Ripal Jariwala, Sally Alrabaa, Chakrapol Sriaroon

Open access · greenAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ case reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Kristen ZeitlerDepartment of Pharmacy, Tampa General Hospital, Tampa, Florida, USA.
Ripal JariwalaDepartment of Pharmacy, University of California San Francisco, San Francisco, California, USA.
Sally AlrabaaDivision of Infectious Diseases and International Medicine, Department of Internal Medicine, University of South Florida, Tampa, Florida, USA.
Chakrapol SriaroonPulmonary/Critical Care, University of South Florida, Tampa, Florida, USA csriaro@health.usf.edu.
University of South Florida · USTampa General Hospital · USUniversity of California, San Francisco · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ruxolitinib (RUX) is a kinase inhibitor used in the treatment of various medical conditions and its mechanism of action involves suppression of the immune system. While beneficial in treatment of polycythemia vera, myelofibrosis and other indications, it can also increase a patient's susceptibility to various infections, including bacterial, viral and fungal. We present a case of a patient being treated with RUX who presented with a disseminated fungal infection. This case emphasises the need for vigilance of endemic fungal infections in individuals who are on RUX therapy.

Indexed as

BlastomycosisPolycythemia VeraPrimary MyelofibrosisHumansNitrilesPyrazolesPyrimidinesNitrilesPyrazolesPyrimidinesruxolitinibinfectionsmalignant disease and immunosuppression

Identifiers

PMID34725058
PMCPMC8562518
OpenAlexW3210660855

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.